Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

Elisa Ferretti, Emma Di Carlo, Emanuela Ognio, Carla Guarnotta, Francesco Bertoni, Anna Corcione, Ignazia Prigione, Giulio Fraternali-Orcioni, Domenico Ribatti, Jean Louis Ravetti, Maurilio Ponzoni, Claudio Tripodo & Vito Pistoia

To cite this article: Elisa Ferretti, Emma Di Carlo, Emanuela Ognio, Carla Guarnotta, Francesco Bertoni, Anna Corcione, Ignazia Prigione, Giulio Fraternali-Orcioni, Domenico Ribatti, Jean Louis Ravetti, Maurilio Ponzoni, Claudio Tripodo & Vito Pistoia (2015) Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma, OncoImmunology, 4:10, e1030560, DOI: 10.1080/2162402X.2015.1030560

To link to this article: http://dx.doi.org/10.1080/2162402X.2015.1030560
Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

Elisa Ferretti1,*, Emma Di Carlo2, Emanuela Ognio3, Carla Guarnotta4, Francesco Berton2, Anna Corcione1, Ignazia Prigione1, Giulio Fraternali-Orcioni5, Domenico Ribatti2, Jean Louis Ravetti6, Maurilio Ponzoni8, Claudio Tripodo4, and Vito Pistoia1

1Laboratorio di Oncologia; Istituto Giannina Gaslini; Genova, Italia; 2Department of Medicine and Sciences of Aging; University and Ce.S.I. Aging Research Center; “G. d’Annunzio” University Foundation; Chieti, Italy; 3IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro; Genova, Italy; 4Tumor Immunology Unit; Department of Health Science; Human Pathology Section; University of Palermo; Palermo, Italy; 5Lymphoma & Genomics Research Program; -IOR- Institute of Oncology Research; and -IOSI- Lymphoma Unit; Oncology Institute of Southern Switzerland; Bellinzona, Switzerland; 6Unit of Pathology; IRCCS AOU San Martino -IST- Istituto Nazionale per la Ricerca sul Cancro; Genova, Italy; 7Department of Basic Medical Sciences; Neurosciences and Sensory Organs; University of Bari Medical School; Bari; Italy; and National Cancer Institute “Giovanni Paolo II”; Bari, Italy; 8Pathology Unit; Unit of Lymphoid Malignancies; San Raffaele Scientific Institute; Milano, Italy

Keywords: angiogenesis, B non-Hodgkin lymphoma, GC B cells, IL-17A, IL-17A receptor, tumor immunology

Abbreviations: Abs, antibodies; B-NHL, B cell non-Hodgkin lymphomas; BL, Burkitt lymphoma; CB, centroblasts; CC, centrocytes; CAM, Chorioallantoic membrane; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; FITC, Fluorescein 15 Isothiocyanate; GC, germinal center; HPSE, Heparan sulfate proteoglycan; ID1, inhibitor of differentiation/DNA binding 1; IGF-1, Insulin-like growth factor 1; IL, Interleukin; LAMA5, Laminin-a5; LECT1, leukocyte cell derived chemotaxin; MRFI, Mean Relative Fluorescence Intensity; m, monoclonal; NOD, Non Obese Diabetic; p, phosphorylated; PE, Phycoerythrin; PGE, prostaglandin; R, receptor; rh, recombinant human; SCID, Severe combined immunodeficiency; TGFB-R1, transforming growth factor b receptor 1; VEGF, vascular growth factor.

Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and OCI-Ly8 cell lines in Severe combined immunodeficiency (SCID)/Non Obese Diabetic (NOD) mice. We found that: (i) B-NHL cell fractions and tonsil GC B cells expressed IL-17RA/IL-17RC, (ii) IL-17A signaled in both cell types through NF-kBp65, but not p38, ERK-1/2, Akt or NF-kBp50/105, phosphorylation, (iii) IL-17A was expressed in T cells and mast cells from neoplastic and normal GC microenvironments, (iv) IL-17A rendered tonsil GC B cells competent to migrate to CXCL12 and CXCL13 by downregulating RGS16 expression; (v) IL-17A stimulated in vitro proliferation of primary B-NHL cells; (vi) IL-17A (1 μg/mouse-per dose) stimulated B-NHL growth in two in vivo models by enhancing tumor cell proliferation and neo-angiogenesis. This latter effect depended on IL-17A-mediated induction of pro-angiogenic gene expression in tumor cells and direct stimulation of endothelial cells. These data define a previously unrecognized role of human IL-17A in promoting growth of GC-derived B-NHL and modulating normal GC B cell trafficking.

Introduction

IL-17A belongs to the IL-17 cytokine superfamily together with five additional structurally related cytokines, namely IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17A is synthesized by Th17 cells, gamma-delta T cells, natural killer T cells, lymphoid tissue-inducer like cells, Paneth cells and neutrophils.1

The biological effects of IL-17 family cytokines are mediated by five different receptor (R) subunits (RA, RB, RC, RD, RE), that are single transmembrane domain-containing proteins which can heterodimerize or homodimerize in different combinations.2 The heterodimer formed by IL-17RA and IL-17RC binds IL-17A, IL-17F and the heterodimeric cytokine IL-17A/IL-17F. 2,3 IL-17RA is expressed ubiquitously, with high levels in the hematopoietic cell compartment.4,5 IL-17RC is highly expressed in epithelial cells of prostate, kidney and joints, and at lower levels in hematopoietic cells.6

The main physiological function of IL-17A is protection from bacterial and fungal infections through recruitment of...
neutrophils to the site of inflammation.4,7 In addition, IL-17A stimulates the production of other cytokines and chemokines such as G-CSF, IL-6 and IL-8.2 Th17 cell-derived IL-17A enhances isotype switching in mouse and human B cells 8 and is involved in the pathogenesis of several autoimmune and allergic diseases. 4 In this respect, IL-17A was found to promote GC formation in different mouse models of human autoimmune or infectious diseases 8-11 via specific signaling pathways.12

In this study, we addressed IL-17AR expression and IL-17A activity on malignant B cells isolated from lymph node biopsies of patients with B-NHL of GC origin, namely follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). In addition, we have investigated expression and function of IL-17AR on human tonsil GC B cells and of IL-17A in the GC microenvironment.

BL and DLBCL are tumors with predominant centroblastic morphology, while FL contains centrocytic and centroblastic components in different ratios depending on tumor grade.13,14 Both DLBCL and FL are highly proliferating tumors that invade the GC and quickly replace the physiological microenvironment. In contrast, FL displays a follicular growth pattern that is partially retained for a long time over the natural history of the disease.13,14 Both DLBCL and FL occur commonly in adults and rarely in children or adolescents.15 DLBCL is the most frequent B-NHL subtype, with approximately one third of cases originating from the transformation of FL.14 BL affects predominantly children or young adults, with frequent intra-abdominal or extranodal involvement.15

We show that IL-17A promotes the growth of B-NHL both in vitro and in vivo by stimulating tumor cell proliferation and neo-angiogenesis. In contrast, IL-17A does not affect proliferation or survival of freshly isolated normal GC B cells, but renders them competent to migrate to CXCL12 and CXCL13 through an NF-kBp65-dependent mechanism, thus contributing to regulate the trafficking of these cells within the GC.

Results

Expression of IL-17AR in human B-NHL lymph node and tonsil germinal center

Both IL-17RA and IL-17RC mRNAs were detected at comparable levels in FL, DLBCL and BL samples (Fig. 1A). Expression of IL-17RA and IL-17RC on the surface of primary neoplastic cells was detected by flow cytometry in 24 lymph node samples of GC-derived B cell lymphoma. In particular, Fig. 1B shows the results obtained with 9 FL, 11 DLBCL and 4 BL cases. The insets in Fig. 1B show a representative staining for IL-17RA and IL-17RC in a FL, BL and DLBCL case, respectively (Mean Relative Fluorescence Intensity (MRFI) ± SD for FL: IL-17RA = 3.1 ± 1.5 and IL-17RC = 2.5 ± 0.5; MRFI ± SD for DLBCL: IL-17RA = 2.5 ± 1.2 and IL-17RC = 2.2 ± 1.5; MRFI ± SD for BL: IL-17RA = 2.8 ± 0.8 and IL-17RC = 2.3 ± 1.5).

IL-17A and IL-17RC expression was next assessed by flow cytometry in different GC B cell subsets freshly isolated from six tonsils. GC B cells (CD38dim CD77− CD39+ IgD−), were found to express IL-17RA and IL-17RC (Fig. 1C). The insets in Fig. 1C show a representative staining of GC B cells for IL-17RA and IL-17RC (MRFI ± SD for GC B cells: IL-17RA = 3.7 ± 1.7 and IL-17RC = 2.5 ± 0.9). Moreover, both centrocytes (CC, CD38dim CD77− B cells) and centroblasts (CB, CD38 bright CD77+ B cells) were found to express IL-17RA and IL-17RC (MRFI ± SD for CB: IL-17RA = 3.2 ± 1.4 and IL-17RC = 2.4 ± 0.6; MRFI ± SD for CC: IL-17RA = 3.4 ± 1.6 and IL-17RC = 2.1 ± 0.7).

IL-17AR function in human normal and malignant GC B cells

IL-17A activates the canonical NF-kB signaling pathway in different cell types.12 As shown in Fig. 2A (upper panel), IL-17A upregulated significantly phosphorylated (p)NF-kBp65, but not NF-kBp65 (similar levels of about 95 ± 3% of expression in treated and untreated cells), in primary B-NHL cells upon incubation for 1 to 30 min with recombinant human (rh) IL-17A, with a peak at 1 min (p = 0.003 for FL and three DLBCL samples). Likewise, a significant upregulation of pNF-kBp65, but not NF-kBp65 (similar levels of about 93 ± 2% of expression in treated and untreated cells), was observed in four tonsil GC B cell suspensions after 10 and 30 min culture with IL-17A (p = 0.01 and = 0.002, respectively), as assessed by flow cytometry (Fig. 2A, lower panels). The faster kinetics of NF-kBp65 phosphorylation in malignant B cells vs. their normal counterparts may depend on intrinsic characteristics of the former cells due to their transformed state. In contrast, IL-17A did not induce phosphorylation of NF-kB p50/105,12 or of p38, ERK1/2, AKT, JNK in either malignant or normal GC B cells.12,16

IL-17A, as well as CD40L tested as positive control,17 significantly increased proliferation of tumor cells over background levels: p = 0.01 and p = 0.009 for five FL samples (Fig. 2B left panel) and p = 0.009 and p = 0.01 for four DLBCL samples (Fig. 2B right panel), respectively. No direct effect of IL-17A on survival or migration of B-NHL cells was observed following co-stimulation with CD40L or anti-IgM/IgG tested alone or in combination (data not shown). For in vitro functional experiments, we tested FL and DLBCL as model of GC-derived B-NHL since the number of cases of these lymphomas was much higher than that of BL.

In contrast, IL-17A did not rescue normal GC B cells from apoptosis nor did it increase the rate of survival induced by rhCD40L stimulation at any time tested (Fig. S1A). Likewise, IL-17A did not affect proliferation of GC B cells either in the presence or absence of rhCD40L (Fig. S1B),18 nor was chemotactic for the latter cells (Fig. S1C).

IL-17A confers migratory competence to CXCL12 and CXCL13 on tonsil GC B cells

We next asked whether IL-17A could modulate CXCR4 and CXCR5 expression and/or function in tonsil GC B cells, thus impacting on their migration within the GC.19 The latter cells, freshly isolated from six different tonsil samples were pre-incubated for 3 or 6 h with or without 20 ng/mL rhIL-17A, and...
subjected to chemotaxis in response to CXCL12 or CXCL13. The proportions of apoptotic GC B cells after 3 and 6 h culture were on average 12 and 22%, respectively, as assessed by Annexin V staining, irrespective of they had been exposed or not to IL-17A. The poor viability of GC B cells is a well-known feature of this cell population.20

Treatment of GC B cells with IL-17A for 3 or 6 h induced their de novo chemotaxis to 300 ng/mL CXCL12 or CXCL13 (p = 0.0005 and p = 0.0007, respectively at both times tested), whereas GC B cells pre-incubated with medium alone never migrated to either chemokine (Fig. 3A).21 Likewise, GC B cells pre-incubated with rhCD40L were attracted by CXCL1222 or CXCL13 (Fig. 3A). The ratio between CB and CC in migrated cells upon stimulation with IL-17A or CD40L was similar to that detected in the same cell fractions before being tested, indicating that CB and CC were equally attracted by both chemokines. Incubation of GC B cells with either rhIL-17A or rhCD40L did not change the MRFI (Fig. 3B) or the percentage of CXCR4+ or CXCR5+ GC B cells (median for CXCR4 of 89 ± 5 % and for CXCR5 of 92 ± 7 % with or without the treatment with rhIL-17A or rhCD40L). Therefore, we tested whether IL-17A driven acquisition of migratory competence to CXCL12

Figure 1. Expression of IL-17A receptor in primary tumor cells from patients with FL, DLBCL or BL and in their normal counterpart. (A) Expression levels of IL-17RA and IL-17RC in FL, DLBCL and BL, as measured using the Affymetrix GeneChip U133 array. Data obtained from the GSE16131 (FL), GSE4475 (DLBCL, BL) datasets, both produced using the Affymetrix U133A. The line in the middle of the box-plot represents the median and the box extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., ±1.5 IQ); outside values are individually plotted. Y-axis, expression values (RMA, Robust Multiarray Average). (B) Neoplastic B cells were stained with anti-κ or anti-λ mAbs in combination with anti-IL-17RA or anti-IL-17RC mAbs and analyzed by flow cytometry. Results for 9 FL, 11 DLBCL and 4 BL are shown in box plot, as median % positive cells, maximum, minimum and first and third quartile. Insets. A representative staining for IL-17RA and IL-17RC in FL, DLBCL and BL is shown, as assessed by flow cytometry. Dark gray histogram: isotype control. Gray histogram: receptor staining. In the plot mean of mean relative fluorescence intensity (MRFI) ± SD is reported. (C) Freshly isolated tonsil MNC were stained with CD38, CD39 or anti-IgD mAbs in combination with anti-IL-17RA or anti-IL-17RC mAbs and analyzed by flow cytometry. Results are mean % positive cells ± SD in GC B cells subset (N = 6). Insets. A representative staining for IL-17RA and IL-17RC in tonsil GC is shown, as assessed by flow cytometry. Gray histogram: isotype control. Dark gray histogram: receptor staining. In the plot mean of MRFI ± SD is reported.
and CXCL13 by tonsil GC B cells was related to downregulation of RGS16, a negative controller of signaling through these chemokine receptors. Indeed, treatment of GC B cells with rhIL-17A or rhCD40L, but not with IFNγ tested as negative control, caused significant downregulation of RGS16 expression (p < 0.005 for rhIL-17A and p = 0.002 for rhCD40L) (Fig. 3C).

Consistent with previous studies, freshly isolated B-NHL cells of GC origin (five FL and four DLCBL samples) expressed CXCR4 and CXCR5 at levels comparable to those detected in normal GC B cells and migrated to CXCL12 and CXCL13. Treatment of B-NHL cells with 20–50 ng/mL rhIL-17A in combination or not with CD40L and/or anti-IgM/IgG did not enhance chemotaxis to either chemokine or expression of the respective receptors CXCR4 and CXCR5 (not shown) nor modulated RGS16 expression (not shown).

**Figure 2.** IL-17A signaling and function in tonsil and neoplastic GC (B) cells. (A) Upper panel: Flow cytometric analysis of pNF-kBp65 in neoplastic cells from three FL (left panel) or three DLBCL (right panel) treated for 0, 1, 10, 30 or 60 min with IL-17A. Results are shown as mean % positive cells ± SD. White histograms: medium alone. Gray histograms: cells stimulated with rhIL-17A. Lower panel: analysis of pNF-kBp65 in isolated GC B cells stimulated for 0, 1, 10, 30 and 60 min with rhIL-17A, as assessed by flow cytometry. Results are mean % positive cells ± SD of four sample tested. White histograms: medium alone. Gray histograms: cells stimulated with rhIL-17A. (B) Primary neoplastic cells from patients with five FL (left panel) and four DLBCL (right panel) were cultured without (Med) or with rhIL-17A or rhCD40L and tested for proliferation by 3H-TdR incorporation. The results shown refer to experiments performed with 20 ng/mL IL-17A, but stimulation of lymphoma cell proliferation was significant also at 10 and 50 ng/mL IL-17A. Results are expressed in box plot, as median % positive cells, minimum, maximum and first and third quartile.

IL-17RA blocking abrogates IL-17-mediated signaling and related functional activities

We next performed functional experiments on neoplastic and normal GC B cells after IL-17RA blocking with a specific monoclonal antibody (mAb), NF-kBp65 phosphorylation was inhibited in both cell types following blocking with IL-17RA mAb, but not with control mAb (Figs. 4A and 5A). Accordingly, IL-17A induced proliferation of primary B-NHL cells (two FL and three DLCBL) was abrogated by pre-treatment of cells with the former, but not the latter, mAb (Fig. 4B). Finally, blocking of IL-17RA abolished IL-17A-induced chemotaxis of tonsil GC B cells to CXCL12 and CXCL13 (Fig. 5B) and downregulation of RGS16 expression in the same cells (Fig. 5C). In contrast, RGS16 downregulation induced by culture of tonsil GC B cells with CD40L was unaffected by IL-17AR blocking (Fig. 5C).

These results demonstrate unambiguously the involvement of IL-17A/IL-17AR in the functional activities of the cytokine in malignant and tonsil GC B cells here reported.

**IL-17A expression in normal and neoplastic germinal center microenvironments**

Immunofluorescence analysis of tonsil tissue sections revealed that IL-17A was predominantly expressed within para-follicular T cell-rich areas where it marked scattered cells with a monocytoid morphology consistent with activated T cells and/or myeloid cells. Double-marker immunofluorescence analysis showed that most IL-17A-positive cells were CD3+ T cells admixed with rare Tryptase+ mast cells (Fig. 6A, B). No CD20+ B cells expressing IL-17A were detected. In B-NHL samples the expression of IL-17A was restricted to scattered reactive CD3+ T cells and occasional Tryptase+ mast cells (Fig. 6C–H).
Expression and function of IL-17AR in GC derived B-NHL cell lines

Five different malignant cell lines derived from GC B-NHL, i.e., SU-DHL-4, DoHH2, OCI-Ly8, Raji and Ramos, were next tested for IL-17AR expression and functionality. As shown in Fig. S2A, all cell lines expressed both IL-17AR subunits, as assessed by flow cytometry. Similarly to primary lymphoma cells, a significantly increased pNF-kBp65 was detected in all cell lines incubated with 20 ng/mL rhIL-17A compared to cells incubated with medium alone. Fig. S2D shows experiments performed with the SU-DHL-4 and OCI-Ly8 cell lines, in which pNF-kBp65 increased significantly over background levels at 1' and remain significant at 60'. These cell lines were selected for the following in vivo experiments.

In vivo effects of IL-17A on B-NHL growth

The tumorigenicity of SU-DHL-4 and OCI-Ly8 cells injected in SCID-NOD mice by different routes of inoculation (i.p., i.v. and s.c.) was tested in order to develop a model suitable for the investigation of the in vivo effects of hrIL-17A. The best rate of growth was observed when neoplastic cells were injected s.c., allowing formation of masses easy to isolate and analyze. Thus, we inoculated 5 × 10⁶ SU-DHL-4 or OCI-Ly8 cells s.c. into 30 NOD/SCID mice. The mice were separated in two groups and treated with 3 weekly doses of rhIL-17A (1 μg/dose), or PBS (controls) for 20 d
The size of tumors formed by SU-DHL-4 cells (Fig. 7A) or Oci-Ly8 cells (Fig. S3) was significantly increased in IL-17A treated vs. untreated mice ($p = 0.0131$ and $0.04$, respectively), indicating that the cytokine stimulated B-NHL growth. The animals did not show any evidence for increased size of internal organs (spleen, liver, lymph nodes, lung, kidney, brain), irrespective of whether they had received IL-17A or PBS, making it unlikely that IL-17A could promote tumor metastasis.

Histological and immunohistochemical studies carried out on lymphoid tumor masses formed by SU-DHL-4 (Fig. 7B) or Oci-Ly8 cells (not shown) provided similar results. Tumors from PBS treated SCID/NOD mice showed a few, but clearly detectable, apoptotic events (as assessed by TUNEL assay) and a distinct microvascular supply (as assessed by laminin and CD31 staining) (Fig. 7B, panels A–D, and Table 1). Treatment with rhIL-17A reduced the frequency of apoptotic events and clearly increased microvascular network development (Fig. 7B, panels E–H). Flow cytometric analysis of cell suspensions from explanted tumors revealed significantly ($p = 0.0087$) increased proportions of Ki-67+ proliferating cells in mice treated with IL-17A vs. PBS (Fig. 7C).

Human angiogenesis PCR array experiments performed with SU-DHL-4 tumors from 4 rhIL-17A treated mice in comparison to tumors from four PBS-treated mice showed that 17A treatment upregulated mRNA expression of the pro-angiogenic genes Heparan sulfate proteoglycan (HPSE), inhibitor of differentiation/DNA binding 1 (ID1), leukocyte cell derived chemotaxin (LECT1), IL-1B, and Laminin-α 5 (LAM5) and downregulated expression of two additional pro-angiogenic genes, namely Insulin-like growth factor 1 (IGF-1) and transforming growth factor β receptor 1 (TGFβ-R1) (Fig. 7D).

Chorioallantoic membrane (CAM) incubation with rhIL-17A for 12 d resulted in a significant angiogenic response in the form of numerous allantoic neovessels developing radially toward the implant in a ‘spoked-wheel’ pattern (mean number of vessels $= 26 \pm 2$ for hIL-17A) (Fig. 7E, panel B). Such response was comparable to that induced by vascular growth factor (VEGF)-A tested as positive control (mean number of vessels $= 24 \pm 3$) (Fig. 7E, panel C). Negative control incubated with PBS was devoid of any pro-angiogenic activity (mean number of vessels $= 7 \pm 1$) (Fig. 7E, panel A). These results provide demonstration of the direct pro-angiogenic activity of IL-17A.

**Discussion**

The GC is a specialized microenvironment formed by proliferating B cells in the follicles of secondary lymphoid organs during T cell-dependent antibody responses to exogenous antigens. The GC dark zone is enriched in proliferating CB that undergo somatic hypermutation of the Ig V region genes resulting into diversification of the IgV repertoire. Thereafter, CB migrate to the light zone where they transform into CC, a minority of which is selected to survive, undergoes Ig isotype switch and
Figure 6. Expression of IL-17A in normal and neoplastic GC microenvironment. (A–H) Double-marker immunofluorescence analysis of IL-17A+ cells within reactive tonsil tissue, and in the neoplastic infiltrates of FL, DLBCL, and BL samples. Most of the IL-17A+ (green) cells co-express (yellow) the T-cell marker CD3 (red) (panel A–C–E–G), which indicates their T-cell nature. In the same cases, scanty IL-17A-expressing (green) tryptase+ (red) mast cells are also found (yellow, panel B–D–F–H). Pictures are relative to full sections of 4 representative cases out of the 26 analyzed. Original magnification, ×400. Double-staining yellow cells are highlighted in an inset present in all panels (A–H) of the Figure. Magnification, ×630. Data were analyzed under a Leica DM3000 optical microscope and captions were collected using a Leica DFC320 digital camera (Leica).
differentiates extrafollicularly into memory B cells or long-lived plasma cells. CB express CXCR4 and are attracted to the dark zone by CXCL12 produced by stromal cells, CC express CXCR5 and are recruited to the light zone along a gradient of CXCL13 produced by FDC. Therefore, CXCL12 and CXCL13 play crucial roles in the regulation of GC B cell trafficking.

Many molecules are involved in GC formation. IL-17A represents a recent addition to such list since it promoted GC formation in a few mouse models of human autoimmune or infectious diseases. Furthermore, IL-17A was found to induce Ig class switching in vitro in mouse and human B cells. So far, little is known on IL-17A in relation to human normal or malignant GC B cell microenvironments.

Variable IL-17A expression was previously detected in lymph nodes and spleen from CLL patients, where IL-17A producing cells were identified as Th17 cells, mastocytes and immature...
In this study, we have investigated the effects of IL-17A on B cells from B-NHL of GC origin and their normal counterparts, i.e., GC B cells. We demonstrated that IL-17RA and IL-17RC were expressed in normal and neoplastic GC B cells, and the heterodimeric IL-17AR signaled exclusively through the canonical NF-kB pathway by phosphorylating NF-kBp65 in both cell types, as previously shown in other cellular models. Nonneoplastic B cells from FL, DLBCL and BL proliferated in vitro in response to IL-17A, suggesting a tumor promoting function of the cytokine. IL-17A-driven cell signaling and proliferation of B-NHL lymphoma cells were abrogated by blocking of IL-17AR with a specific mAb. Since IL-17A expression was detected in CD3+ T cells and occasional tryptase-positive mast cells present in B-NHL microenvironment, we next investigated the in vivo effects of IL-17A on the growth of human SU-DHL-4 and Oci-Ly8 DLBCL cells, tested as models of B-NHL cells. IL-17A increased tumor growth in SCID/NOD mice by enhancing significantly malignant cell migration to CXCL12.40 In the present study, pre-incubation of human GC B cells with IL-17A conferred the capacity to migrate to CXCL12 and CXCL13 in the absence of CD40L stimulation. The mechanism underlying such effects was found to be related to downregulation of RGS16 expression operated by both IL-17A or CD40L, highlighting a common mechanism for these molecules.

Detection of IL-17A expressing cells with a predominant localization in the para-follicular T cell-rich areas of tonsil GC, expression of IL-17A receptor by GC B cells, and IL-17A-mediated induction of migratory competence to CXCL12 and CXCL13 in GC B cells all point to IL-17A as a previously unknown regulator of B cell trafficking in the GC of secondary lymphoid organs. Our results are consistent with the demonstration of a role of IL-17A in the development of GC in an autoimmune mouse model. Although RGS16 was found also in the latter studies to be target of IL-17A activity, the final result of this molecular interaction was an increased spontaneous GC formation mediated by abolished B cell chemotaxis to CXCL12 and enhanced retention of GC B cells in the GC.

Table 1. Immunohistochemical assessment of microvessels and apoptotic cells in tumors developed after SU-DHL-4 cell injection in PBS or hrIL-17A treated mice

| Microvessels | Apoptotic index % |
|-------------|------------------|
| PBS         | 84 ± 2.5         |
| hrIL-17A    | 149 ± 3.0*       |
| PBS         | 15.7 ± 5.0       |
| hrIL-17A    | 6.2 ± 3.2        |

Table 1. Immunohistochemical assessment of microvessels and apoptotic cells in tumors developed after SU-DHL-4 cell injection in PBS or hrIL-17A treated mice

Apoptotic cell and microvessel count was performed as reported in Methods. Eight fields were examined for each tumor section and three sections per tumor (three cytokine treated vs. three PBS treated) were evaluated. Results are expressed as mean ± SD of TUNEL positive cells/number of total cells (×600) or, CD31 positive vessels per field (×400) evaluated on formalin-fixed sections by immunohistochemistry.

§Values significantly different (p <0.05) from corresponding values in tumors developed in PBS-treated mice.

The role of IL-17A and of Th17 cells in tumor growth is controversial. IL-17A is released in the tumor microenvironment of human cervical malignancies, non-small cell lung carcinoma, hepatocellular carcinoma and multiple myeloma, for which the cytokine was found to enhance tumor growth. In contrast, IL-17A was shown to inhibit indirectly the growth of mouse mastocytoma and plasmacytoma through T-cell-dependent mechanisms. Th17 related IL-21 may counteract tumor progression in primary B-NHL with ocular localization. Moreover, elevated levels of circulating Th17 cells in CLL correlated with better prognosis and longer survival.

In this study, we have investigated the effects of IL-17A on B cells from lymph nodes of B-NHL patients were found to contain scanty Th17 cells. In another study, in vitro expanded T cells from myeloid cells. In the present mouse angiogenesis PCR array analysis. In these experiments, no modulation of gene expression was detected in tumors from IL-17A treated vs. control mice, indicating that the stimulation of tumor angiogenesis observed in the former mice depended on the direct activity of the cytokine on human lymphoma cells.

Different studies have demonstrated the importance of neoangiogenesis among the pro-tumoral effects of IL-17A, highlighting the ability of the cytokine to promote neo-vascular formation through direct and indirect mechanisms. Thus, IL-17A stimulated migration of vascular endothelial cells and induced fibroblasts and tumor cells to produce pro-angiogenic growth factors and cytokines, such as prostaglandin (PGE)1, PGE2, VEGF, keratinocyte-derived chemokine or macrophage inflammatory protein-2. In a human non-small cell lung cancer model, IL-17A increased in vivo tumor growth and angiogenesis via a CXCR2-dependent mechanism.

Here we show that hrIL-17A had an intrinsic direct pro-angiogenic activity, as assessed by the ability of the cytokine to stimulate new vessel formation in the CAM assay. It is conceivable that in our experiments the intrinsic pro-angiogenic activity of IL-17A was a major player in the enhancement of tumor angiogenesis since expression of a relatively limited number of pro-angiogenic genes was disclosed in tumor masses by PCR-array experiments.

At variance with that observed with B-NHL cells, IL-17A did not influence proliferation of normal tonsil GC B cells, possibly due to intrinsic proneness of these cells to apoptosis and the inability of IL-17A to counteract this latter process.

We have previously shown that freshly isolated human GC B cells do not migrate to CXCL12 although they express CXCR4. Nonetheless, incubation of the latter cells with CD40L was found to render them competent to migrate to CXCL12. In the present study, pre-incubation of human GC B cells with IL-17A conferred the capacity to migrate to CXCL12 and CXCL13 in the absence of CD40L stimulation. The mechanism underlying such effects was found to be related to downregulation of RGS16 expression operated by both IL-17A or CD40L, highlighting a common mechanism for these molecules.

www.tandfonline.com OncoImmunology e1030560-9
and in vitro vs. in vivo studies) and to the strong inflammatory environment associated with mouse autoimmunity compared that of human tonsil.

In conclusion, this study delineates previously unrecognized roles of IL-17A in neoplastic and normal GC. In the latter context, IL-17A unambiguously promotes the growth of human B-NHL by enhancing tumor cell proliferation and neo-angiogenesis, paving the way to future studies addressing the IL-17A/IL-B-NHL by enhancing tumor cell proliferation and neo-angiogenesis. In the former context, IL-17A appears to participate in the regulation of GC B cell chemotaxis in the normal GC microenvironment.

### Materials and Methods

#### Patients and controls

Heavily infiltrated lymph nodes from patients with FL (n = 15; 9 males and 6 females, age range: 46–61), DLBCL (n=17, 9 males and 8 females, age range: 49–65) and BL (n = 12, 8 males and 4 female, age range: 7–18), biopsied for diagnostic purposes, were obtained after informed consent in accordance with the Declaration of Helsinki. Diagnosis of FL, DLBCL and BL was established according to the criteria of the Revised European–American Classification of Lymphoid Neoplasms. All patients were studied at diagnosis and were untreated. Twelve tonsils, surgically removed due to localized inflammation, were obtained after informed consent. The study was approved by the Institutional Review Board of Istituto Giannina Gaslini, Genova, Italy on October 27th, 2005.

#### Cell isolation and culture

Tonsil B cells (>95 % CD19+ cells) were isolated as reported and enriched for GC B cells (> 95% CD19+, CD38hi, CD10+, CD44− cells) by centrifugation on a discontinuous (60–30%) Percoll (Pharmacia) density gradient followed by depletion of CD39+ naïve and memory B cells. For in vitro experiments, we used either freshly isolated or frozen tonsil B cells obtaining superimposable results. The latter cells were cryopreserved in freezing solution containing 50% RPMI 1640 (Sigma Chemical Company), 40% FBS (Sigma), and 10% DMSO (Sigma).

Malignant B cell suspensions (>80–85% CD19+ cells) were first isolated from lymph nodes as reported, then cryopreserved in freezing solution and further enriched (at least 96%) after thawing by removing (i) residual normal B cells according to the expression of the Immunoglobulin light chain not expressed by the malignant clone and (ii) other contaminant cell types (i.e., CD3+, CD56+ and CD14+ cells), through immunomagnetic bead manipulation (Milteny, Miltenyi Biotec). The human SU-DHL-4 (of DLBCL origin), DoHH2 (of FL origin) and Raji and Ramos (of BL origin) were used, together with the Oci-Ly8 cell line that is considered with a DLCBL origin. All cell lines were provided 2 yr ago by InterlabCell Line Collection (Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy) that certifies their origin by multiplex short tandem repeat profiling. These cell lines, that were revalidated 4 months ago by Interlab using the same assay, were cultured in RPMI 1640 medium (Sigma) supplemented with 10% FBS (Sigma).

#### Antibodies and flow cytometry

The following mAbs were used: Phycoerythrin (PE)-conjugated anti-IL-17RA, Alexa Fluor 488 anti-IL-17RC (R&D System Inc.); PE or Fluorescein Isothiocyanate (FITC) anti-κ and anti-λ lg light chains, PE-CD10 (R&D System); unconjugated-CD39 (Immunotech); PC7-CD19, PC5-CD38, FITC-CD44, PC5 and FITC-CD3 (Beckman Coulter); FITC-anti human Ki67 (DAKO); PE or FITC anti-IgD (Biolegend). PeCy7-CD39 and FITC-CD68 were from eBiosciences (eBiosciences). Anti-human RGS-16 unconjugated mAb was from Abcam (Abcam). For intracellular flow cytometry detection, cells were stained with anti-Ki67 or anti-RGS16 using cytofix/cytoperm kit (Becton-Dickinson). Cells were stained with fluorochrome-conjugated mAbs, or unconjugated mAbs followed by fluorochrome-conjugated secondary reagents, or with isotype- and fluorochrome-matched control antibodies. Cells were run on a Gallios instrument (Beckman Coulter) and data were analyzed using the Kaluza software (Beckman Coulter). Data were expressed as percentage of positive cells or MRFI, calculated as follows: fluorescence intensity obtained with specific mAb/fluorescence intensity obtained with irrelevant isotype-matched mAb. For cytofluorimetric analysis of tonsil mononuclear cells, we first gated the lymphocyte population based upon physical parameters and then gated lymphocytes stained with a specific mAb, e.g., CD19.

#### Cell signaling

NF-kBp65 (Ser536) phosphorylation was investigated by flow cytometry. Cells were treated for 0–1–5–10–30–60 min with or without (medium) 20 ng/ml rhIL-17A and stained with an Alexa 488-conjugated anti-pNF-kBp65 mAb (Cell Signaling Technology) and an unconjugated anti-NF-kBp65 polyclonal Ab (Cell Signaling Technology) according to the instructions of the manufacturer. In brief, cultured cells were collected, fixed with 2% paraformaldehyde for 10 min at 37°C, incubated with 90% ice-cold methanol for 30 min to permeabilize the cells, and subsequently stained with the specific Ab for 1h at room temperature. The same protocol was used to investigate the phosphorylation of NF-kBp105, ERK1/2, Akt, JNK (Cell Signaling Technology). Cells were washed and run on Gallios cytometer. Data were analyzed using the Kaluza software.

#### Cell proliferation, apoptosis and chemotaxis

Normal and neoplastic cells were analyzed for proliferation and apoptosis in presence or absence of 10–20–50-ng/mL rhIL-17A (see the Supplemental Methods). Chemotaxis was investigated using 5 μm pore-size transwell plates (Costar) as reported (see the Supplemental Methods).

#### Blocking experiments

Normal and neoplastic B cells were pre-incubated for 20 min with 2 μg/mL of an IgG1 blocking mouse mAb to human IL-17RA (R&D System, clone#133617) or of mouse IgG1 control mAb (R&D System) at 37°C. Thereafter, cells were cultured...
with 50 ng/mL rhIL-17A for different times and subjected to functional tests.

**Immunofluorescence**

Tissue samples selected for immunofluorescent analyses were retrieved from the archives of the Human Pathology Section, Department of Health Sciences, University of Palermo. Formalin-fixed and paraffin-embedded tissue sections from six FL, six DLBCL and eight BL lymph nodes, as well as from six tonsils with reactive follicular hyperplasia were tested. The immunofluorescence techniques are detailed in the Supplemental Methods online.

**Gene expression profiling**

Raw expression profiles (CEL files) were downloaded from three publicly available data-sets (GSE2350, GSE4475, GSE16131) and individually imported and normalized using RMA (Robust Multiarray Average) algorithm in Partek Genomics Suite 6.4 (Partek, St. Louis, MO, USA). Box-plots were created with Stata/SE v.12.1 (StataCorp, College Station, TX, USA) and differential expression among groups was evaluated with the Wilcoxon rank-sum test. A p value lower than 0.05 was considered statistically significant.

**In vivo studies**

Four–six week old SCID-NOD mice (Harlan Laboratories) were housed under specific pathogen-free conditions. All procedures involving animals were performed in accordance with national and international current regulations (D.l.vo 27/01/1992, n.116, European Economic Community Council Directive 86/609, OJL 358, December 1, 1987). Thirty animals were injected s. c. in the left flank with $5 \times 10^6$ SU-DHL-4 cells and separated in two groups of 15 mice each. The same protocol was applied to 30 SCID/NOD mice injected s.c. in the left flank with $2.5 \times 10^6$ Oci-Ly8 cells. The first group of mice was treated with 3 weekly doses of rhIL-17A (1 μg/mouse per dose) starting one day after injection of tumor cells. The second group was treated with PBS (controls) following the same time schedule. The concentration of IL-17A to be injected in vivo was chosen on the basis of previous studies. Twenty days after tumor cell inoculation, mice were killed since signs of poor health such as enlarging tumor masses and presence of ruffled fur, became evident and autopsies were carried out. Tumor masses were explanted, measured as described and used for counting the number of TUNEL positive cells/number of total cells in the viable neoplastic tissue under a microscope $\times 600$ field ($\times 60$ objective and $\times 10$ ocular lens; 0.120 mm$^2$ per field).

**Angiogenesis PCR-Array**

RNA was extracted from mouse tumors using Qiagen (Hilden) kit, reverse transcribed and processed using human or mouse Angiogenesis RT$^2$ PCR Array (SABioscience), as described. PCR was performed on ABI Prism 7700 Sequence Detector (Applied Biosystems).

**CAM assay**

CAM assay was carried out as previously reported to investigate the angiogenic activity of IL-17A. The technique is detailed in the Supplemental Methods online.

**Statistical analysis**

Differences in tumor volume, chemotaxis, RGS16 expression, apoptotic and proliferating cells and NF-kBp65 phosphorylation were calculated using Mann–Whitney test comparing two independent samples, with 99% confidence interval (GraphPad Prism 3). All statistical tests were two tailed. A p value lower than 0.05 was considered statistically significant. Quantitative studies of stained sections were performed independently by two pathologists in a blind fashion. Differences in the number of apoptotic cells and tumor microvessels in immunohistological studies were evaluated by Student’s t test. All statistical tests were two-tailed and a p value lower than 0.05 was considered statistically significant.

**Disclosure of Potential Conflicts of Interest**

The samples used for this study were obtained from patients after informed consent in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board of Istituto Giannina Gaslini, Genova, Italy on October 27th, 2005.

**Acknowledgments**

The authors thank Dr. Francesco Annunziato for reading the manuscript and providing insightful criticism and suggestion and Dr. Sarah Gaffen for helpful suggestions.

**Supplemental Material**

Supplemental data for this article can be accessed on the publisher’s website.
References

1. Gaffen SL. An overview of IL-17 function and signaling. J Biol Chem 2004; 279:4832-7; PMID:1507318; http://dx.doi.org/10.1074/jbc.M400600200.

2. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556-7; PMID:19575026; http://dx.doi.org/10.1038/nri2586.

3. Tjoa JH, Goglio A, Mandel M, Vanden Bossche T, Guelinckx J, Derry J, Tockier J, Peschon J. Cutting edge: interleukin-17 signals through a heteromeric receptor complex. J Immunol 2006; 177:36-9; PMID:16785495; http://dx.doi.org/10.4049/jimmunol.177.1.36.

4. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujiyama Y, Bamba T. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002; 282:G1035-44; PMID:12016619; http://dx.doi.org/10.1152/ajpgi.00490204.

5. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff SE, Franz B, Wucherpfennig K, Turley S, Carroll MC, Jansen JH, de Jong D, Kluin PM. A new role for IL1B gene variants in the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10:778-85; PMID:19483719; http://dx.doi.org/10.1038/ni.1741.

6. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton J, Cyster JG. Germinal-center-derived lymphomas seen through their cellularization and cellular dynamics. Immunity 2007; 26:39-50; PMID:1755032; http://dx.doi.org/10.1016/j.immuni.2007.03.015.

7. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional implications for tumor cell invasion. J Biol Chem 2004; 279:8047-55; PMID:14630925; http://dx.doi.org/10.1074/jbc.M304872200.

8. Carbone A, Goglio A, Bagni AL, Malorni W, Dennis EA, Brown CR. Cyclosporine-A orchestrates germinal center formation and antibody class-switch via regulation of IL-17. J Immunol 2009; 183:5644-53; PMID:19843949; http://dx.doi.org/10.4049/jimmunol.0901495.

9. Algood HM, Allen SS, Washington MK, Peek RM, Jr., Nakamura A, McAllister F, Hishinuma T, Goto J, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Naka K, Tartour E et al. Differential roles of interleukin-17A and -17F in host defense against mucocutaneous bacterial infection and allergic responses. Immunity 2009; 30:108-19; PMID:19144317; http://dx.doi.org/10.1016/j.immuni.2008.11.009.

10. Allen CD, Okada T, Cyster JG. Germinal-center organization and cell biology of human B cells. J Exp Med 2001; 194:21-5; PMID:11255877; http://dx.doi.org/10.1084/jem.20011190.

11. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton J, Cyster JG. Germinal-center-derived lymphomas seen through their cellularization and cellular dynamics. Immunity 2007; 26:39-50; PMID:1755032; http://dx.doi.org/10.1016/j.immuni.2007.03.015.

12. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2000; 18:628-35; PMID:10772680; http://dx.doi.org/10.1146/annurev.immunol.18.1.628.

13. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton J, Cyster JG. Germinal-center-derived lymphomas seen through their cellularization and cellular dynamics. Immunity 2007; 26:39-50; PMID:1755032; http://dx.doi.org/10.1016/j.immuni.2007.03.015.

14. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton J, Cyster JG. Germinal-center-derived lymphomas seen through their cellularization and cellular dynamics. Immunity 2007; 26:39-50; PMID:1755032; http://dx.doi.org/10.1016/j.immuni.2007.03.015.

15. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton J, Cyster JG. Germinal-center-derived lymphomas seen through their cellularization and cellular dynamics. Immunity 2007; 26:39-50; PMID:1755032; http://dx.doi.org/10.1016/j.immuni.2007.03.015.
44. Benjamin D, Magrath IT, Maguire R, Janus C, Todd HD, Parsons RG. Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt’s and non-Burkitt’s type. J Immunol 1982; 129:1336-42; PMID:6286763

45. Lafarge S, Hamzeh-Cognasse H, Chavarin P, Genin C, Garraud O, Cognasse F. A flow cytometry technique to study intracellular signals NF-kappaB and STAT3 in peripheral blood mononuclear cells. BMC Mol Biol 2007; 8:64; PMID:17663801; http://dx.doi.org/10.1186/1471-2199-8-64

46. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37:382-90; PMID:15778709; http://dx.doi.org/10.1038/ng1532

47. Hummel M, Bentink S, Berger H, Klappet W, Wessendorff S, Barth TF, Bernd HW, Cogliatti SB, Dierlam J, Feller AC et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419-30; PMID:16760442; http://dx.doi.org/10.1056/NEJMoa055351

48. Leich E, Salaverria I, Rea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009; 114:826-34; PMID:19471018; http://dx.doi.org/10.1182/blood-2009-01-198540

49. Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ogna E, Montagna D, Pistoa V, Airoldi I. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 2010; 133:99-105; PMID:20705102; http://dx.doi.org/10.1016/j.imlet.2010.08.002

50. Ferretti E, Montagna D, Di Carlo E, Cocco C, Ribatti D, Ogna E, Sorrentino C, Laini D, Bertaina A, Locatelli F et al. Absence of IL-12Rbeta2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RGammaC-deficient mice. Leukemia 2012; 26:225-35; PMID:21844875; http://dx.doi.org/10.1038/leu.2011.213